Deutsche Bank Ag\ Denali Therapeutics Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 239,946 shares of DNLI stock, worth $5.59 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

239,946

Previous 223,400 7.41%

Holding current value

$5.59 Million

Previous $5.19 Million 34.74%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$20.96 - $31.05 $346,804 - $513,753	16,546 Added 7.41%	239,946 $6.99 Million
Q2 2024 Aug 14, 2024	SELL	$14.96 - $23.22 $105,183 - $163,259	-7,031 Reduced 3.05%	223,400 $5.19 Million
Q1 2024 May 15, 2024	BUY	$15.83 - $23.35 $1.82 Million - $2.69 Million	115,079 Added 99.76%	230,431 $4.73 Million
Q4 2023 Feb 14, 2024	SELL	$16.2 - $23.18 $18,565 - $26,564	-1,146 Reduced 0.98%	115,352 $2.48 Million
Q3 2023 Nov 09, 2023	SELL	$20.63 - $30.17 $585,458 - $856,194	-28,379 Reduced 19.59%	116,498 $2.4 Million
Q2 2023 Aug 14, 2023	BUY	$23.37 - $32.96 $330,638 - $466,318	14,148 Added 10.82%	144,877 $4.28 Million
Q1 2023 May 15, 2023	BUY	$21.91 - $32.67 $438,178 - $653,367	19,999 Added 18.06%	130,729 $3.01 Million
Q4 2022 Feb 13, 2023	BUY	$26.28 - $33.92 $259,646 - $335,129	9,880 Added 9.8%	110,730 $3.08 Million
Q3 2022 Nov 14, 2022	SELL	$25.97 - $38.53 $245,338 - $363,992	-9,447 Reduced 8.57%	100,850 $3.1 Million
Q2 2022 Aug 11, 2022	SELL	$20.88 - $35.19 $54,642 - $92,092	-2,617 Reduced 2.32%	110,297 $3.25 Million
Q1 2022 May 13, 2022	SELL	$29.0 - $47.27 $157,122 - $256,108	-5,418 Reduced 4.58%	112,914 $3.63 Million
Q4 2021 Feb 11, 2022	BUY	$42.59 - $55.02 $98,638 - $127,426	2,316 Added 2.0%	118,332 $5.28 Million
Q3 2021 Nov 04, 2021	SELL	$48.48 - $78.23 $49,546 - $79,951	-1,022 Reduced 0.87%	116,016 $5.85 Million
Q2 2021 Aug 11, 2021	BUY	$50.3 - $78.44 $2.93 Million - $4.57 Million	58,249 Added 99.08%	117,038 $9.18 Million
Q1 2021 May 13, 2021	BUY	$53.8 - $81.53 $371,327 - $562,720	6,902 Added 13.3%	58,789 $3.36 Million
Q4 2020 Feb 16, 2021	BUY	$36.89 - $93.56 $409,847 - $1.04 Million	11,110 Added 27.25%	51,887 $4.35 Million
Q3 2020 Nov 12, 2020	SELL	$23.13 - $38.84 $19,544 - $32,819	-845 Reduced 2.03%	40,777 $1.46 Million
Q2 2020 Aug 13, 2020	SELL	$16.01 - $28.82 $467,123 - $840,881	-29,177 Reduced 41.21%	41,622 $1.01 Million
Q1 2020 May 14, 2020	SELL	$14.2 - $27.98 $190,379 - $375,127	-13,407 Reduced 15.92%	70,799 $1.24 Million
Q4 2019 Feb 14, 2020	SELL	$14.4 - $19.99 $284,889 - $395,482	-19,784 Reduced 19.02%	84,206 $1.47 Million
Q3 2019 Nov 14, 2019	BUY	$15.32 - $21.92 $844,469 - $1.21 Million	55,122 Added 112.8%	103,990 $1.59 Million
Q2 2019 Aug 14, 2019	BUY	$18.5 - $28.14 $417,156 - $634,528	22,549 Added 85.68%	48,868 $1.01 Million
Q1 2019 May 15, 2019	SELL	$17.99 - $24.65 $15,273 - $20,927	-849 Reduced 3.13%	26,319 $608,000
Q4 2018 Feb 14, 2019	SELL	$13.88 - $21.75 $1.06 Million - $1.66 Million	-76,228 Reduced 73.72%	27,168 $561,000
Q3 2018 Dec 21, 2021	BUY	$12.46 - $21.74 $149,058 - $260,075	11,963 Added 13.08%	103,396 $2.25 Million
Q3 2018 Nov 14, 2018	BUY	$12.46 - $21.74 $718,505 - $1.25 Million	57,665 Added 170.77%	91,433 $1.99 Million
Q2 2018 Apr 21, 2020	BUY	$15.25 - $21.02 $97,020 - $133,729	6,362 Added 23.21%	33,768 $514,000
Q2 2018 Aug 14, 2018	BUY	$15.25 - $21.02 $94,153 - $129,777	6,174 Added 29.08%	27,406 $417,000
Q1 2018 Oct 18, 2019	BUY	$15.36 - $24.8 $56,724 - $91,586	3,693 Added 21.06%	21,232 $417,000
Q1 2018 May 15, 2018	BUY	$15.36 - $24.8 $269,399 - $434,967	17,539 New	17,539 $345,000

Others Institutions Holding DNLI

# of Institutions

226

Shares Held

119M

Call Options Held

60.6K

Put Options Held

48.4K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.13B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account